NetScientific Shares Jump as Portfolio Company PDS Collaborates With Merck & Co
03 Octobre 2019 - 03:28PM
Dow Jones News
By Adria Calatayud
Shares in NetScientific PLC (NSCI.LN) rose Thursday after it
said portfolio company PDS Biotechnology Corp. (PDSB) will
collaborate with U.S. drug maker Merck & Co. Inc. (MRK) in a
phase II clinical trial.
NetScientific, a London-based healthcare technology company,
said the trial will study PDS's lead product, PDS0101, in
combination with Merck's cancer drug Keytruda as a first line
treatment in patients with recurrent or metastatic head and neck
cancer and high-risk human papillomavirus-16 infection.
Shares in NetScientific at 1256 GMT were up 40% at 8.75
pence.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 03, 2019 09:13 ET (13:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024